Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET3 | O43151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.46 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.46 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.46 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.46 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 4/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8191035 | 0.99 | TET3 (0.45) | TET3KMT2AFBXL19CXXC5KDM2B | |
| SCHEMBL7603077 | 0.92 | HRH1 (0.46) | TET3KMT2AFBXL19CXXC5KDM2B | |
| SCHEMBL7605289 | 0.90 | HRH1 (0.45) | KMT2AHRH1DRD2LMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL8186699 | 0.89 | HRH1 (0.45) | KMT2AHRH1LMNACYP1A2CYP3A4 | |
| SCHEMBL8186016 | 0.86 | OPRM1 (0.60) | DRD2SLC6A4ADRA1ADRD3OPRK1 | |
| SCHEMBL652677 | 0.85 | DRD2 (0.54) | DRD2ADRA1AOPRM1OPRL1 | |
| SCHEMBL145501 | 0.80 | OPRM1 (0.61) | KMT2ALMNASLC6A4ADRA1AOPRK1 | |
| SCHEMBL8191292 | 0.78 | OPRM1 (0.58) | KMT2ALMNASLC6A4ADRA1AOPRK1 | |
| SCHEMBL12121517 | 0.78 | HRH1 (0.45) | KMT2AHRH1DRD2LMNACYP1A2 | |
| SCHEMBL10287852 | 0.78 | DRD2 (0.46) | KMT2AHRH1DRD2LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | LUBRIZOL CORPORATION, THE | 2002-04-18 | — | — | US | claimed |
| EP-1047673-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 2000-11-02 | — | — | EP | claimed |
| US-6048856-A | ANALGESICS; ANTIINFLAMMATORY AGENTS | NOVO NORDISK A/S (DK) | 2000-04-11 | — | — | US | claimed |
| WO-1999031058-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1999-06-24 | — | — | WO | claimed |
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | LUBRIZOL CORPORATION, THE | 2002-04-18 | — | — | US | disclosed |
| EP-1135129-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2001-09-26 | — | — | EP | disclosed |
| EP-1047673-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 2000-11-02 | — | — | EP | disclosed |
| WO-2000032193-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2000-06-08 | — | — | WO | disclosed |
| US-6048856-A | ANALGESICS; ANTIINFLAMMATORY AGENTS | NOVO NORDISK A/S (DK) | 2000-04-11 | — | — | US | disclosed |
| WO-1999031058-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | VEGFA, KDR, FLT4 | TET3 1175/4885KMT2A 3298/4885FBXL19 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.